Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 13.12% is 124% above its 5-year average of -55.11%, near the high end of its 5-year range (-208.76%–23.93%).
As of the fiscal period ended Tuesday, June 30, 2026. 136.31% above its 12-month average of -36.14%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 13.12%.
RETURN ON INVESTED CAPITAL (ROIC)
13.12%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-36.14%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-32.44%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-55.11%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+136.31%
CURRENT VS 3Y AVG
+140.46%
CURRENT VS 5Y AVG
+123.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 830 covered companies
CURRENT VS SECTOR MEDIAN
+136.82%
vs the sector median at left
Spero Therapeutics, Inc.
Market Cap
$68.32M
Return on Invested Capital (ROIC)
13.12%
TTM Avg
-36.14%
3Y Avg
-32.44%
5Y Avg
-55.11%
Market Cap
$68.08M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-401.98%
3Y Avg
-245.26%
5Y Avg
-207.94%
Market Cap
$68.43M
Return on Invested Capital (ROIC)
-10.85%
TTM Avg
-101.00%
3Y Avg
-120.85%
5Y Avg
-96.47%
Market Cap
$67.52M
Return on Invested Capital (ROIC)
-40.22%
TTM Avg
-72.23%
3Y Avg
-74.75%
5Y Avg
-58.95%
Market Cap
$69.75M
Return on Invested Capital (ROIC)
-6.75%
TTM Avg
20.47%
3Y Avg
-36.30%
5Y Avg
-23.36%
Market Cap
$66.31M
Return on Invested Capital (ROIC)
-37.01%
TTM Avg
-30.52%
3Y Avg
-23.08%
5Y Avg
-17.79%
Market Cap
$66.20M
Return on Invested Capital (ROIC)
-83.74%
TTM Avg
-153.15%
3Y Avg
-164.21%
5Y Avg
-165.99%
Market Cap
$64.80M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-86.10%
3Y Avg
-83.22%
5Y Avg
-74.34%
Market Cap
$72.09M
Return on Invested Capital (ROIC)
-159.24%
TTM Avg
-170.07%
3Y Avg
-147.54%
5Y Avg
-112.39%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | $68.32M | 13.12% | -36.14% | -32.44% | -55.11% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.08M | N/A | -401.98% | -245.26% | -207.94% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.43M | -10.85% | -101.00% | -120.85% | -96.47% |
| iBio, Inc. (IBIO)vs › | $67.52M | -40.22% | -72.23% | -74.75% | -58.95% |
| Champions Oncology, Inc. (CSBR)vs › | $69.75M | -6.75% | 20.47% | -36.30% | -23.36% |
| XBiotech Inc. (XBIT)vs › | $66.31M | -37.01% | -30.52% | -23.08% | -17.79% |
| Cingulate Inc. (CING)vs › | $66.20M | -83.74% | -153.15% | -164.21% | -165.99% |
| Gossamer Bio, Inc. (GOSS)vs › | $64.80M | N/A | -86.10% | -83.22% | -74.34% |
| Gain Therapeutics, Inc. (GANX)vs › | $72.09M | -159.24% | -170.07% | -147.54% | -112.39% |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | -139.74% | -190.33% | -1114.56% | -840.48% |
ROIC
13.1%
ROE
16.7%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | 13.12% |
| 2026-03-31 | 23.93% |
| 2025-12-31 | 9.88% |
| 2025-09-30 | -110.36% |
| 2025-06-30 | -117.29% |
| 2025-03-31 | -147.19% |
| 2024-12-31 | -116.05% |
| 2024-09-30 | -1.25% |
| 2024-06-30 | 12.78% |
| 2024-03-31 | 15.32% |
| 2023-12-31 | 13.12% |
| 2023-09-30 | -2.06% |
| 2023-06-30 | -15.65% |
| 2023-03-31 | -28.73% |
| 2022-12-31 | -40.25% |
| 2022-09-30 | -191.50% |
| 2022-06-30 | -208.76% |
| 2022-03-31 | -76.63% |
| 2021-12-31 | -57.72% |
| 2021-09-30 | -61.70% |
| 2021-06-30 | -70.29% |
| 2021-03-31 | -59.76% |
| 2020-12-31 | -56.87% |
| 2020-09-30 | -61.13% |
| 2020-06-30 | -108.44% |
| 2020-03-31 | -91.21% |
| 2019-12-31 | -78.66% |
| 2019-09-30 | -49.68% |
| 2019-06-30 | -36.21% |
| 2019-03-31 | -31.93% |
| 2018-12-31 | -36.68% |
| 2018-09-30 | -36.33% |
| 2018-06-30 | -67.82% |
| 2018-03-31 | -59.75% |
| 2017-12-31 | -48.91% |
| 2017-09-30 | -148.08% |
| 2017-06-30 | -102.37% |
